Actually Obleix is right n = 10 is quite low (although fine for rare diseases). Even though it says statistically significant we will need to get way more data on who the patients where (m/f, age, progression of disease, amt of ARB, blood-drug levels etc.) before we can break out the champagne. Secondly, only seven of those qualified for final analysis.
It does help to say that with a small study, we will need more info as investors/doctors/patients/mgmt before we are confident of us shareholders getting some big pay days. De-risking this will include some form of licensing deal I would imagine.
That is why a Ph3 is needed next with a much larger pop. Else on just the Ph2 we could go straight to commercialization.
As a holder I am happy for the company and everyone involved. As an investor, I await more info and a ph3.
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-59
-
- There are more pages in this discussion • 228 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.020(4.60%) |
Mkt cap ! $228.5M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 41.0¢ | $731.5K | 1.748M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 269178 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 14070 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |